CA3035443A1 - Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof - Google Patents
Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof Download PDFInfo
- Publication number
- CA3035443A1 CA3035443A1 CA3035443A CA3035443A CA3035443A1 CA 3035443 A1 CA3035443 A1 CA 3035443A1 CA 3035443 A CA3035443 A CA 3035443A CA 3035443 A CA3035443 A CA 3035443A CA 3035443 A1 CA3035443 A1 CA 3035443A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- amino acid
- influenza
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 235
- 239000013638 trimer Substances 0.000 title claims abstract description 20
- 101710154606 Hemagglutinin Proteins 0.000 title claims description 563
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title claims description 563
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title claims description 563
- 101710176177 Protein A56 Proteins 0.000 title claims description 563
- 239000000185 hemagglutinin Substances 0.000 title claims description 116
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 274
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 269
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 244
- 239000002105 nanoparticle Substances 0.000 claims abstract description 202
- 229960005486 vaccine Drugs 0.000 claims abstract description 74
- 108050000784 Ferritin Proteins 0.000 claims abstract description 67
- 102000008857 Ferritin Human genes 0.000 claims abstract description 67
- 238000008416 Ferritin Methods 0.000 claims abstract description 56
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 47
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 440
- 150000001413 amino acids Chemical class 0.000 claims description 244
- 125000000539 amino acid group Chemical group 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 42
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 35
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 35
- 230000028993 immune response Effects 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 28
- 230000002163 immunogen Effects 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 17
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 claims description 15
- 238000011144 upstream manufacturing Methods 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000003556 assay Methods 0.000 abstract description 80
- 230000001681 protective effect Effects 0.000 abstract description 28
- 102000037865 fusion proteins Human genes 0.000 abstract description 11
- 108020001507 fusion proteins Proteins 0.000 abstract description 11
- 235000001014 amino acid Nutrition 0.000 description 264
- 235000018102 proteins Nutrition 0.000 description 260
- 229940024606 amino acid Drugs 0.000 description 255
- 241000700605 Viruses Species 0.000 description 87
- 230000035772 mutation Effects 0.000 description 79
- 241001500351 Influenzavirus A Species 0.000 description 43
- 208000037797 influenza A Diseases 0.000 description 42
- 108090000765 processed proteins & peptides Proteins 0.000 description 39
- 238000002965 ELISA Methods 0.000 description 28
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 25
- 238000013461 design Methods 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- 210000004899 c-terminal region Anatomy 0.000 description 21
- 150000004676 glycans Chemical class 0.000 description 21
- 230000003472 neutralizing effect Effects 0.000 description 20
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 18
- 235000018417 cysteine Nutrition 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 16
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 235000004400 serine Nutrition 0.000 description 14
- 239000004474 valine Substances 0.000 description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 239000004471 Glycine Substances 0.000 description 12
- 241000712431 Influenza A virus Species 0.000 description 12
- 241000702437 Parvovirus H3 Species 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 238000002523 gelfiltration Methods 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 11
- 235000004279 alanine Nutrition 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 238000011725 BALB/c mouse Methods 0.000 description 10
- 101710157275 Ferritin subunit Proteins 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 229930182817 methionine Natural products 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 229960000310 isoleucine Drugs 0.000 description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
- 239000004473 Threonine Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 235000009582 asparagine Nutrition 0.000 description 8
- 229960001230 asparagine Drugs 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 235000004554 glutamine Nutrition 0.000 description 8
- 229960003971 influenza vaccine Drugs 0.000 description 8
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 235000008521 threonine Nutrition 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 235000009697 arginine Nutrition 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- -1 cysteine amino acid Chemical group 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 235000014304 histidine Nutrition 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000012575 bio-layer interferometry Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000009918 complex formation Effects 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000000937 dynamic scanning calorimetry Methods 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000001338 self-assembly Methods 0.000 description 6
- 238000004904 shortening Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229940031348 multivalent vaccine Drugs 0.000 description 5
- 238000002439 negative-stain electron microscopy Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 4
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 4
- 241001164676 Influenza A virus (A/Denmark/35/2005(H3N2)) Species 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 238000002820 assay format Methods 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000034303 cell budding Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000893512 Aquifex aeolicus Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102220639274 DNA-binding protein inhibitor ID-3_V59N_mutation Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102220298208 rs1273257287 Human genes 0.000 description 2
- 102220265632 rs876660420 Human genes 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 1
- IVKWMMGFLAMMKJ-XVYDVKMFSA-N Ala-His-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N IVKWMMGFLAMMKJ-XVYDVKMFSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 description 1
- RCENDENBBJFJHZ-ACZMJKKPSA-N Asn-Asn-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCENDENBBJFJHZ-ACZMJKKPSA-N 0.000 description 1
- AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 description 1
- RATOMFTUDRYMKX-ACZMJKKPSA-N Asp-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N RATOMFTUDRYMKX-ACZMJKKPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- WTXCNOPZMQRTNN-BWBBJGPYSA-N Cys-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)O WTXCNOPZMQRTNN-BWBBJGPYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102220491927 Golgin subfamily A member 6-like protein 2_N54H_mutation Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000312828 Influenza A virus (A/Anhui/DEWH72-03/2013(H7N9)) Species 0.000 description 1
- 241001029997 Influenza A virus (A/Bangladesh/541/2012(H3N2)) Species 0.000 description 1
- 241001029996 Influenza A virus (A/Bangladesh/542/2012(H3N2)) Species 0.000 description 1
- 241001029994 Influenza A virus (A/Bangladesh/558/2012(H3N2)) Species 0.000 description 1
- 241000931768 Influenza A virus (A/Beijing/3/2013(H7N9)) Species 0.000 description 1
- 241001461279 Influenza A virus (A/Hong Kong/470129/2013(H7N9)) Species 0.000 description 1
- 241000177930 Influenza A virus (A/Japan/AF2844/2012(H3N2)) Species 0.000 description 1
- 241000484849 Influenza A virus (A/North Carolina/AF2716/2011(H3N2)) Species 0.000 description 1
- 241000927072 Influenza A virus (A/Norway/70/2005(H3N2)) Species 0.000 description 1
- 241000440547 Influenza A virus (A/Norway/88/2003(H3N2)) Species 0.000 description 1
- 241001592328 Influenza A virus (A/Sao Paulo/89403/2010(H3N2)) Species 0.000 description 1
- 241000628325 Influenza A virus (A/Shanghai/JS01/2013(H7N9)) Species 0.000 description 1
- 241000036388 Influenza A virus (A/Shenzhen/SP44/2014(H7N9)) Species 0.000 description 1
- 241001241954 Influenza A virus (A/Texas/2977/2012(H3N2)) Species 0.000 description 1
- 241001592316 Influenza A virus (A/Tocantins/979/2010(H3N2)) Species 0.000 description 1
- 241000774367 Influenza A virus (A/Tunisia/17332/2011(H3N2)) Species 0.000 description 1
- 241001055238 Influenza A virus (A/duck/Chiba/24-203-44/2012(H7N1)) Species 0.000 description 1
- 241000866330 Influenza A virus (A/mallard/Italy/4810-7/2004(H7N7)) Species 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 101710199771 Matrix protein 1 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- CDBXVDXSLPLFMD-BPNCWPANSA-N Tyr-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDBXVDXSLPLFMD-BPNCWPANSA-N 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 244000156473 Vallaris heynei Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960001226 live attenuated influenza Drugs 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 229940039328 nanoparticle-based vaccine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220234445 rs1064796078 Human genes 0.000 description 1
- 102200101795 rs72554306 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nanotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383267P | 2016-09-02 | 2016-09-02 | |
| US62/383,267 | 2016-09-02 | ||
| PCT/US2017/049894 WO2018045308A1 (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3035443A1 true CA3035443A1 (en) | 2018-03-08 |
Family
ID=59887401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3035443A Pending CA3035443A1 (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11338033B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3506938A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7183149B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240042570A (cg-RX-API-DMAC7.html) |
| CN (2) | CN110167585B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017321883B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019004189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3035443A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL265121B2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201901790YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018045308A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015054639A1 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus vaccines |
| KR20240042570A (ko) * | 2016-09-02 | 2024-04-02 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 |
| GB2578163A (en) * | 2018-10-19 | 2020-04-22 | Univ Pretoria | Plant produced avian influenza antigens and their uses in diagnostic assays and devices |
| US12433943B2 (en) | 2019-02-08 | 2025-10-07 | University Of Washington | Nanoparticle-based influenza virus vaccines and uses thereof |
| EP4110384A4 (en) * | 2020-02-26 | 2024-07-31 | The Wistar Institute of Anatomy and Biology | COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF |
| CN111560074B (zh) * | 2020-03-20 | 2021-07-09 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 |
| WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
| JP2024511206A (ja) | 2021-03-26 | 2024-03-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| WO2022200582A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| US20250281595A1 (en) | 2021-06-28 | 2025-09-11 | Glaxosmithkline Biologicals Sa | Novel influenza antigens |
| WO2023044388A1 (en) * | 2021-09-16 | 2023-03-23 | Emergent Product Development Gaithersburg Inc. | Vaccine compositions |
| WO2023061993A1 (en) | 2021-10-13 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Polypeptides |
| GB202219228D0 (en) | 2022-12-20 | 2023-02-01 | Glaxosmithkline Biologicals Sa | Novel influenza antigens |
| CN115850396B (zh) * | 2022-12-22 | 2024-02-06 | 北京吉诺卫生物科技有限公司 | 一种rsv纳米颗粒疫苗及其制备方法与应用 |
| WO2024131862A1 (zh) * | 2022-12-22 | 2024-06-27 | 北京吉诺卫生物科技有限公司 | 一种rsv疫苗及其制备方法与应用 |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2024167855A1 (en) | 2023-02-06 | 2024-08-15 | Emergent Product Development Gaithersburg Inc. | Influenza hemagglutinin constructs and compositions |
| WO2024197134A1 (en) * | 2023-03-21 | 2024-09-26 | President And Fellows Of Harvard College | Coronavirus spike protein-based vaccines |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
| ES2307093T3 (es) | 2001-10-01 | 2008-11-16 | THE GOVERNMENT OF THE USA, AS REPR. BY SECRETARY, DEPT. HEALTH & HUMAN SERVICES, NAT. INST OF HEALTH | Desarrollo de un vacuna preventiva para la infeccion por filovirus en primates. |
| US20050108791A1 (en) | 2001-12-04 | 2005-05-19 | Edgerton Michael D. | Transgenic plants with improved phenotypes |
| AU2003228962A1 (en) | 2002-05-10 | 2003-11-11 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| EP2351770A1 (en) | 2002-07-17 | 2011-08-03 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| DE60333306D1 (de) | 2002-08-30 | 2010-08-19 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen |
| CA2529647C (en) | 2003-06-16 | 2013-08-13 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| GB0319797D0 (en) | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
| US7897408B2 (en) | 2005-09-12 | 2011-03-01 | Japan Science And Technology Agency | Method for producing CdS-apoferritin and ZnS-apoferritin complexes |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| JP2010514439A (ja) | 2006-12-29 | 2010-05-06 | インスティティ パスツール オブ シャンハイ | インフルエンザヘマグルチニンで偽型化したレンチウイルス及びその使用方法 |
| EP2160198A2 (en) | 2007-05-31 | 2010-03-10 | Statens Serum Institut | Influenza vaccines |
| US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| CA2696764A1 (en) | 2007-08-20 | 2009-02-26 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| EP2235043A2 (en) | 2008-02-01 | 2010-10-06 | Alpha-O Peptides AG | Self-assembling peptide nanoparticles useful as vaccines |
| JP5382489B2 (ja) | 2008-03-29 | 2014-01-08 | 国立大学法人 奈良先端科学技術大学院大学 | 円偏光発光性ナノ微粒子 |
| US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| JP2012521786A (ja) * | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| RU2579903C2 (ru) | 2009-09-22 | 2016-04-10 | Медикаго Инк. | Способ получения вирусоподобных частиц растений |
| US20120219584A1 (en) | 2009-10-05 | 2012-08-30 | The United States Of America As Represented By The Secretary, Department Of Health | Protection against pandemic and seasonal strains of influenza |
| JP2013520167A (ja) | 2010-02-18 | 2013-06-06 | テクノヴァックス，インコーポレイテッド | 万能ウイルス様粒子（ｖｌｐ）インフルエンザワクチン |
| CA2821492A1 (en) * | 2010-12-13 | 2012-06-21 | The University Of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| EP2758075B1 (en) | 2011-09-20 | 2023-05-03 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| CA2849822C (en) | 2011-09-23 | 2021-05-11 | Gary J. Nabel, M.D. | Novel influenza hemagglutinin protein-based vaccines |
| JP6294828B2 (ja) * | 2011-11-28 | 2018-03-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | インフルエンザウイルスワクチンおよびその使用 |
| WO2013177444A2 (en) | 2012-05-23 | 2013-11-28 | The Board Of Trustees Of The Leland Stanford Junior University | Influenza vaccine constructs |
| SG11201504728RA (en) * | 2012-12-18 | 2015-07-30 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
| MY190097A (en) * | 2013-05-30 | 2022-03-28 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| WO2015054639A1 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus vaccines |
| SI3063273T1 (sl) * | 2013-10-28 | 2020-03-31 | Blue Sky Vaccines Gmbh | Vektor virusa gripe za viroterapijo |
| EP3148578B1 (en) | 2014-05-27 | 2022-07-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Stabilized influenza hemagglutinin stem region trimers and uses thereof |
| BR112016030577A8 (pt) | 2014-07-10 | 2021-07-20 | Janssen Vaccines & Prevention Bv | polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes |
| US9969986B2 (en) | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| AU2015373928B2 (en) | 2014-12-31 | 2019-10-17 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
| EP3474893A1 (en) * | 2016-06-27 | 2019-05-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| KR20240042570A (ko) * | 2016-09-02 | 2024-04-02 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 |
| WO2021231729A1 (en) * | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
-
2017
- 2017-09-01 KR KR1020247010062A patent/KR20240042570A/ko active Pending
- 2017-09-01 BR BR112019004189A patent/BR112019004189A2/pt unknown
- 2017-09-01 KR KR1020197009334A patent/KR20190056382A/ko not_active Ceased
- 2017-09-01 SG SG11201901790YA patent/SG11201901790YA/en unknown
- 2017-09-01 AU AU2017321883A patent/AU2017321883B2/en active Active
- 2017-09-01 SG SG10201912944QA patent/SG10201912944QA/en unknown
- 2017-09-01 CN CN201780066267.2A patent/CN110167585B/zh active Active
- 2017-09-01 CA CA3035443A patent/CA3035443A1/en active Pending
- 2017-09-01 CN CN202410185751.9A patent/CN118146389A/zh active Pending
- 2017-09-01 JP JP2019512267A patent/JP7183149B2/ja active Active
- 2017-09-01 IL IL265121A patent/IL265121B2/en unknown
- 2017-09-01 IL IL315821A patent/IL315821A/en unknown
- 2017-09-01 EP EP17768316.6A patent/EP3506938A1/en active Pending
- 2017-09-01 WO PCT/US2017/049894 patent/WO2018045308A1/en not_active Ceased
- 2017-09-01 IL IL303650A patent/IL303650B2/en unknown
- 2017-09-01 US US16/329,592 patent/US11338033B2/en active Active
-
2022
- 2022-05-11 US US17/742,201 patent/US11793871B2/en active Active
- 2022-10-07 AU AU2022246465A patent/AU2022246465B2/en active Active
- 2022-11-22 JP JP2022186724A patent/JP7500692B2/ja active Active
-
2023
- 2023-10-20 US US18/491,193 patent/US20240050554A1/en active Pending
-
2024
- 2024-06-05 JP JP2024091170A patent/JP2024123036A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL265121B1 (en) | 2023-07-01 |
| US20190192651A1 (en) | 2019-06-27 |
| IL303650B2 (en) | 2025-02-01 |
| AU2017321883B2 (en) | 2022-07-07 |
| KR20240042570A (ko) | 2024-04-02 |
| CN110167585B (zh) | 2024-03-08 |
| US11338033B2 (en) | 2022-05-24 |
| CN118146389A (zh) | 2024-06-07 |
| JP7183149B2 (ja) | 2022-12-05 |
| IL303650A (en) | 2023-08-01 |
| BR112019004189A2 (pt) | 2019-06-25 |
| JP2023018073A (ja) | 2023-02-07 |
| AU2022246465A1 (en) | 2022-11-17 |
| WO2018045308A1 (en) | 2018-03-08 |
| IL303650B1 (en) | 2024-10-01 |
| AU2022246465B2 (en) | 2024-05-30 |
| JP2019537424A (ja) | 2019-12-26 |
| SG11201901790YA (en) | 2019-03-28 |
| US20240050554A1 (en) | 2024-02-15 |
| JP7500692B2 (ja) | 2024-06-17 |
| IL265121B2 (en) | 2023-11-01 |
| JP2024123036A (ja) | 2024-09-10 |
| US11793871B2 (en) | 2023-10-24 |
| AU2017321883A1 (en) | 2019-04-18 |
| US20220339278A1 (en) | 2022-10-27 |
| CN110167585A (zh) | 2019-08-23 |
| EP3506938A1 (en) | 2019-07-10 |
| SG10201912944QA (en) | 2020-02-27 |
| KR20190056382A (ko) | 2019-05-24 |
| IL315821A (en) | 2024-11-01 |
| IL265121A (cg-RX-API-DMAC7.html) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022246465B2 (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| US12268737B2 (en) | Stabilized influenza hemagglutinin stem region trimers and uses thereof | |
| US9441019B2 (en) | Influenza hemagglutinin protein-based vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |
|
| EEER | Examination request |
Effective date: 20220623 |